Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial

A. Gronchi, S. Ferrari, V. Quagliuolo, J.M. Broto, A.L. Pousa, G. Grignani, U. Basso, J.-Y. Blay, O. Tendero, R.D. Beveridge, V. Ferraresi, I. Lugowska, D.F. Merlo, V. Fontana, E. Marchesi, D.M. Donati, E. Palassini, E. Palmerini, R. De Sanctis, C. Morosi & 8 others S. Stacchiotti, S. Bagué, J.M. Coindre, A.P. Dei Tos, P. Picci, P. Bruzzi, P.G. Casali, Manuela Monti

Research output: Contribution to journalArticle

119 Citations (Scopus)
Original languageItalian
Pages (from-to)812-822
Number of pages11
JournalThe Lancet Oncology
Volume18
Issue number6
DOIs
Publication statusPublished - 2017

Cite this

@article{9608138a7a994cf6a5136465bbf3f708,
title = "Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial",
author = "A. Gronchi and S. Ferrari and V. Quagliuolo and J.M. Broto and A.L. Pousa and G. Grignani and U. Basso and J.-Y. Blay and O. Tendero and R.D. Beveridge and V. Ferraresi and I. Lugowska and D.F. Merlo and V. Fontana and E. Marchesi and D.M. Donati and E. Palassini and E. Palmerini and {De Sanctis}, R. and C. Morosi and S. Stacchiotti and S. Bagu{\'e} and J.M. Coindre and {Dei Tos}, A.P. and P. Picci and P. Bruzzi and P.G. Casali and Manuela Monti",
note = "Cited By :10 Export Date: 22 February 2018",
year = "2017",
doi = "10.1016/S1470-2045(17)30334-0",
language = "Italian",
volume = "18",
pages = "812--822",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "6",

}

TY - JOUR

T1 - Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial

AU - Gronchi, A.

AU - Ferrari, S.

AU - Quagliuolo, V.

AU - Broto, J.M.

AU - Pousa, A.L.

AU - Grignani, G.

AU - Basso, U.

AU - Blay, J.-Y.

AU - Tendero, O.

AU - Beveridge, R.D.

AU - Ferraresi, V.

AU - Lugowska, I.

AU - Merlo, D.F.

AU - Fontana, V.

AU - Marchesi, E.

AU - Donati, D.M.

AU - Palassini, E.

AU - Palmerini, E.

AU - De Sanctis, R.

AU - Morosi, C.

AU - Stacchiotti, S.

AU - Bagué, S.

AU - Coindre, J.M.

AU - Dei Tos, A.P.

AU - Picci, P.

AU - Bruzzi, P.

AU - Casali, P.G.

AU - Monti, Manuela

N1 - Cited By :10 Export Date: 22 February 2018

PY - 2017

Y1 - 2017

U2 - 10.1016/S1470-2045(17)30334-0

DO - 10.1016/S1470-2045(17)30334-0

M3 - Articolo

VL - 18

SP - 812

EP - 822

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 6

ER -